Cornell Research Foundation Inc.

Louisiana State University and Agricultural & Mechanical College

University of Minnesota

Ra Pharmaceuticals, Inc.

Other

Purdue Research Foundation

Agricultural and Mechanical College

The Board of Supervisors of La State University

Robert P Hammer

Francis Barany

George Barany

Matthew Lubin

Monib Zirvi

Maria Kempe

Herman Blok

Alonso Ricardo

Douglas A Treco

Michelle Denise Hoarty

Kathleen Seyb

Guo-Qing Tang

Daniel Elbaum

Zhaolin Wang

Zhong Ma

Hong Zheng

Ping Ye

Kristopher Josephson

Nathan Ezekiel Nims

Ketki Ashok Dhamnaskar

Kelley Cronin Larson

Sarah Jacqueline Perlmutter

Phillip Belgrader

Mark L McLaughlin

Thomas Scott Yokum

Frederick M Enright

William Hansel

Philip H Elzer

Sylvia Tobe

Ramin Farzaneh-Far

Steven James DeMarco

Vaishnavi Rajagopal

Douangsone D Vadysirisack

Sita Aggarwal

Lawrence W Langley

Donald E Bergstrom

Steven A Soper

Yanwen Fu

Norman P Gerry

Tod J Miller

Joseph M Day

Maria Da Graça Henriques Vicente

Serhii Pakhomov

Timothy J Jensen

Michael W Allen

Irina V Nesterova

Joseph P Day

Nancy E Witowski

Karin Musier-Forsyth

Qinghong Xu

Lin Chen

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Modulation of complement activity

The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.

Modulators of complement activity

Conjugating LHRH to(LHRH-) substantially enhances the bioavailability of, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.

Curcumin conjugates for treating and preventing cancers

The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.

Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays

Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.

The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference.

Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions

Growing community of inventors

Baton Rouge, LA, United States of America

Robert P Hammer